← Back to Search

HPV Vaccine Strategies for Human Papillomavirus (HPVV Trial)

N/A

Recruiting

Led By Erin Hahn, PhD

Research Sponsored by Kaiser Permanente

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up year 1 through year 4

Awards & highlights

HPVV Trial Summary

This trial is testing whether a tailored or prescribed HPV vaccine intervention can improve provider recommendations and HPV vaccination rates.

Who is the study for?

This trial is for pediatric clinics, their staff including physicians, nurses, and administrators, as well as parents of children aged 9-12 eligible for the HPV vaccine. It excludes healthcare workers outside pediatrics and parents of children over 12 or without a clinic visit in the study period.Check my eligibility

What is being tested?

The trial compares three strategies to improve HPV vaccination rates: a 'local-tailored' strategy addressing local barriers; a 'prescribed' strategy targeting pre-selected barriers; and usual care with no research-led activities.See study design

What are the potential side effects?

Since this study focuses on implementation strategies rather than medical treatments, it does not directly involve side effects from interventions like drugs or vaccines.

HPVV Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ year 1 through year 4

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~year 1 through year 4

This trial's timeline: 3 weeks for screening, Varies for treatment, and year 1 through year 4 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Proportion of children 9-12 years old who received the first dose of the HPV vaccine - EMR

Proportion of children 9-12 years old who received the first dose of the HPV vaccine -EMR

Secondary outcome measures

Provider Recommendation - survey

Other outcome measures

Fidelity - survey

HPV vaccine series completion - EMR

Parent satisfaction with HPV vaccine communication - survey

+3 more

HPVV Trial Design

3Treatment groups

Experimental Treatment

Active Control

Group I: Prescribed StrategyExperimental Treatment1 Intervention

The intervention arm will include 20 clinics randomly assigned to the intervention arm.. All physicians, nurses, department administrator,s and other staff members from the pediatric departments randomized to this arm will be included in the study, as well as parents of HPV vaccine eligible children (9-12 years old) who had one or more visits with their pediatric provider during the data collection period.

Group II: Local TailoringExperimental Treatment1 Intervention

The intervention arm will include 20 clinics randomly assigned to the intervention arm. All physicians, nurses, department administrator and other staff members from the pediatric departments randomized to this arm will be included in the study, as well as parents of HPV vaccine eligible children (9-12 years old) who had one or more visits with their pediatric provider during the data collection period.

Group III: Usual CareActive Control1 Intervention

The intervention arm will include 20 clinics randomly assigned to the usual care arm. All physicians, nurses, department administrators,s and other staff members from the pediatric departments randomized to this arm will be included in the study, as well as parents of HPV vaccine eligible children (9-12 years old) who had one or more visits with their pediatric provider during the data collection period.

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Kaiser PermanenteLead Sponsor

538 Previous Clinical Trials

24,023,093 Total Patients Enrolled

National Cancer Institute (NCI)NIH

13,665 Previous Clinical Trials

40,835,854 Total Patients Enrolled

Erin Hahn, PhDPrincipal InvestigatorKPSC Department of Research and Evaluation

Media Library

Prescribed Strategy Clinical Trial Eligibility Overview. Trial Name: NCT05365048 — N/A

Human Papillomavirus Research Study Groups: Local Tailoring, Usual Care, Prescribed Strategy

Human Papillomavirus Clinical Trial 2023: Prescribed Strategy Highlights & Side Effects. Trial Name: NCT05365048 — N/A

Prescribed Strategy 2023 Treatment Timeline for Medical Study. Trial Name: NCT05365048 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What criteria must one meet to qualify for this research endeavor?

"This medical trial is seeking to enroll 90,000 participants who are between 21 and 70 years old and have a confirmed diagnosis of human papillomavirus."

Answered by AI

What is the maximum number of participants in this research project?

"That is correct. The clinical trial registry hosted on the website of clinicaltrials.gov confirms that this experiment, which was originally posted in March 21 2022, is currently recruiting applicants. It will require 90 000 participants from only one medical centre."

Answered by AI

Are researchers accepting new participants in this investigation?

"Yes, clinicaltrials.gov data confirms that this medical study is currently recruiting patients; the trial was first posted on March 21st 2022 and has been recently updated as of May 3rd 2022. Approximately ninety thousand individuals are being sought for participation from a single location."

Answered by AI